metformin has been researched along with Muscular Dystrophy, Duchenne in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The L-arginine/nitric oxide synthase (NOS) pathway is considered to be altered in muscular dystrophy such as Becker muscular dystrophy (BMD)." | 9.27 | Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications. ( Bollenbach, A; Bonati, U; Fischer, D; Hafner, P; Hanff, E; Kayacelebi, AA; Tsikas, D, 2018) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 9.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| "The L-arginine/nitric oxide synthase (NOS) pathway is considered to be altered in muscular dystrophy such as Becker muscular dystrophy (BMD)." | 5.27 | Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications. ( Bollenbach, A; Bonati, U; Fischer, D; Hafner, P; Hanff, E; Kayacelebi, AA; Tsikas, D, 2018) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 5.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| "Five ambulatory, genetically confirmed Duchenne muscular dystrophy patients aged between 7–10 years were treated with L-arginine (3 x 2." | 2.82 | Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study. ( Bieri, O; Bonati, U; Deuster, S; Erne, B; Fischer, D; Fischmann, A; Frank, S; Gloor, M; Gueven, N; Hafner, P; Neuhaus, C; Peters, T; Pohlman, U; Rubino, D; Rutz, E; Schmid, M; Sinnreich, M, 2016) |
| "It is thought that it exerts its anti-cancer effect through the inhibition of the mammalian target of rapamycin (mTOR) signalling pathway." | 2.61 | The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. ( Amin, S; Lux, A; O'Callaghan, F, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hafner, P | 4 |
| Bonati, U | 4 |
| Klein, A | 1 |
| Rubino, D | 3 |
| Gocheva, V | 2 |
| Schmidt, S | 1 |
| Schroeder, J | 1 |
| Bernert, G | 1 |
| Laugel, V | 1 |
| Steinlin, M | 1 |
| Capone, A | 1 |
| Gloor, M | 2 |
| Bieri, O | 2 |
| Hemkens, LG | 1 |
| Speich, B | 1 |
| Zumbrunn, T | 2 |
| Gueven, N | 3 |
| Fischer, D | 4 |
| Mantuano, P | 1 |
| Sanarica, F | 1 |
| Conte, E | 1 |
| Morgese, MG | 1 |
| Capogrosso, RF | 1 |
| Cozzoli, A | 1 |
| Fonzino, A | 1 |
| Quaranta, A | 1 |
| Rolland, JF | 1 |
| De Bellis, M | 1 |
| Camerino, GM | 1 |
| Trabace, L | 1 |
| De Luca, A | 1 |
| Hanff, E | 1 |
| Bollenbach, A | 1 |
| Kayacelebi, AA | 1 |
| Tsikas, D | 1 |
| Amin, S | 1 |
| Lux, A | 1 |
| O'Callaghan, F | 1 |
| Ljubicic, V | 1 |
| Jasmin, BJ | 1 |
| Erne, B | 1 |
| Schmid, M | 1 |
| Pohlman, U | 1 |
| Peters, T | 1 |
| Rutz, E | 1 |
| Frank, S | 1 |
| Neuhaus, C | 1 |
| Deuster, S | 1 |
| Fischmann, A | 1 |
| Sinnreich, M | 1 |
| Casteels, K | 1 |
| Fieuws, S | 1 |
| van Helvoirt, M | 1 |
| Verpoorten, C | 1 |
| Goemans, N | 1 |
| Coudyzer, W | 1 |
| Loeckx, D | 1 |
| de Zegher, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular Dystrophy"[NCT01995032] | Phase 3 | 47 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [NCT02516085] | Phase 1 | 5 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Cell Line, Tumor; Clinical Trials as Topic; Cogniti | 2019 |
5 trials available for metformin and Muscular Dystrophy, Duchenne
2 other studies available for metformin and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
Topics: Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypoglycemic Agents; Isomet | 2018 |
Metformin increases peroxisome proliferator-activated receptor γ Co-activator-1α and utrophin a expression in dystrophic skeletal muscle.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Hypoglycemic Agents; M | 2015 |